Gritstone to Participate in H.C. Wainwright Global Investment Conference
May 17 2022 - 5:00PM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company that aims to develop the world’s most potent vaccines,
today announced that Andrew Allen, M.D., Ph.D., Co-founder,
President and Chief Executive Officer of Gritstone, will
participate in a fireside chat at the H.C. Wainwright Global
Investment Conference, which is being held virtually and in-person
from May 23-26, 2022.
The fireside chat will be available on-demand beginning Tuesday,
May 24 at 7 a.m. ET via the Investors & Media section of
Gritstone’s website at
https://ir.gritstonebio.com/investors/events. An archived replay
will be accessible for 30 days following the event.
About Gritstone bioGritstone bio, Inc. (Nasdaq:
GRTS) is a clinical-stage biotechnology company that aims to create
the world’s most potent vaccines. We leverage our innovative
vectors and payloads to train multiple arms of the immune system to
attack critical disease targets. Independently and with our
collaborators, we are advancing a portfolio of product candidates
to treat and prevent viral diseases and solid tumors in pursuit of
improving patient outcomes and eliminating disease.
www.gritstonebio.com
Gritstone Forward-Looking StatementsThis press
release contains forward-looking statements, including, but not
limited to, statements related to the potential of Gritstone’s
therapeutic programs; the advancements in Gritstone’s ongoing
clinical trials; the timing of data announcements related to
ongoing clinical trials and the initiation of future clinical
trials. Such forward-looking statements involve substantial risks
and uncertainties that could cause Gritstone’s research and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the drug development process, including Gritstone’s programs’ early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, Gritstone’s ability to successfully
establish, protect and defend its intellectual property and other
matters that could affect the sufficiency of existing cash to fund
operations. Gritstone undertakes no obligation to update or revise
any forward-looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the business of Gritstone in general, see
Gritstone’s most recent Quarterly Report on Form 10-Q filed on May
5, 2022 and Gritstone’s future reports to be filed with the
Securities and Exchange Commission. The forward-looking statements
in this press release are based on information available to
Gritstone as of the date hereof. Gritstone disclaims any obligation
to update any forward-looking statements, except as required by
law.
Gritstone ContactsInvestors:George E.
MacDougallDirector, Investor Relations & Corporate
CommunicationsGritstone bioir@gritstone.com
Media:Dan Budwick1AB(973) 271-6085dan@1abmedia.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024